When Adult-Use Eclipses Medical Cannabis: Challenges and Solutions for Patients

Wishing you a joyful August and a wonderful end to summer!

The medical cannabis movement began with a compassionate mission—providing relief for patients with severe conditions like HIV/AIDS, cancer, epilepsy, and chronic pain. Over the years, advocates successfully implemented regulated systems that prioritized patient needs. However, the rise of recreational cannabis markets has sidelined these patients, creating significant challenges in access, affordability, and care quality. This blog explores how the increasing commercialization of cannabis impacts medical users and offers actionable strategies to restore balance.

The Shift from Medical to Recreational Markets is Eroding Access to Patient-Focused Products
Recreational cannabis legalization has shifted the dispensary focus toward high-THC products like edibles, vapes, and concentrates, leaving therapeutic options scarce. Products with balanced CBD-to-THC ratios or high-CBD formulations—essential for many medical patients—often disappear from shelves.

• Consider Olivia, a lupus patient relying on a 20:1 CBD-to-THC formula, experienced this firsthand. When her state legalized recreational cannabis, her local dispensary stopped carrying her preferred tinctures, forcing her to seek alternatives. “It’s frustrating,” she says. “The products aren’t designed for people like me anymore.” Unfortunately, when medical items are unavailable, patients turn elsewhere, reducing demand and accelerating the shift to recreational-focused inventory.

Knowledge Gaps in Professional Support
Patients often turn to healthcare providers or dispensary staff for advice on cannabis treatments. However, many physicians lack sufficient training on cannabinoid therapies, and poorly trained budtenders frequently prioritize easy sales over medical guidance.

• Consider Martin, a veteran managing PTSD. Seeking a high-CBD strain for his anxiety, he encountered a budtender unfamiliar with his needs. “They tried to sell me a THC-heavy edible instead,” Martin recalls. Without options or guidance, he purchased an unsuitable product, worsening his anxiety. Such cases underscore the urgent need for better education on the endocannabinoid system (ECS) and patient care in both healthcare and retail settings.

Systemic Barriers in Medical Cannabis Access & Financial Strain from High Taxes
Although intended to ease financial burdens, many state medical cannabis programs impose excessive taxes, treating medical and recreational buyers the same. Tax rates often exceed 40%, making cannabis unaffordable for those with chronic conditions.

• Consider Jenny, a chemotherapy patient whose expenses nearly doubled overnight after recreational legalization. Despite having a medical card, inconsistent tax exemptions left her struggling. “This isn’t a luxury for me; it’s my medicine,” Jenny says. Reforming tax policies to exempt medical patients from high levies is crucial for equitable care.

Risks of Synthetic Cannabinoids
The rise of synthetic cannabinoid receptor agonists, or SCRAs, further complicates the market. Commonly marketed as “legal highs,” these compounds, such as JWH-018, are often more potent than natural cannabis but pose severe health risks, including psychosis, seizures, and cardiac issues. Unregulated production frequently introduces contaminants, increasing toxicity.

• Consider Elyse, who has fibromyalgia, unknowingly purchased a THC-O product she believed was therapeutic. Instead, severe dizziness and anxiety landed her in the ER. Stories like hers highlight the need for regulations on synthetic compounds and clearer labeling to help patients identify safe products.

Addressing Stigma and Misconceptions
The recreational cannabis boom has shifted public perception of cannabis as a lifestyle product, overshadowing its therapeutic value.

• Consider Paul, who relies on CBD/THC patches for spinal injury pain, this stigma is disheartening. “People assume I’m just trying to get high,” Paul says. Raising awareness of cannabis’s medicinal benefits through educational campaigns and clinician advocacy is vital to restoring its legitimacy.

Recommendations for a Balanced Approach – Addressing these challenges requires systemic changes to protect medical cannabis patients. Key recommendations include:

• Protecting Tax Exemptions – Implement policies ensuring medical cannabis purchases are tax-free for certified patients.
• Expanding Product Variety – Mandate that dispensaries stock diverse formulations, including high-CBD and balanced cannabinoid options.
• Improving Training – Require comprehensive ECS and cannabis therapeutics training for healthcare professionals and budtenders alike.
• Regulating Synthetic Compounds – Enforce strict oversight of synthetic cannabinoid production while promoting access to safe, plant-based options.
• Reframing Cannabis as Medicine – Promote awareness of cannabis’s therapeutic applications through clinician-led education and advocacy and general public education.

A Path Forward for Patients and Providers – The cannabis industry’s shift toward recreational markets should not come at the expense of its foundational mission—compassionate care for patients. Implementing product regulations, reforming tax policies, and enhancing education are key steps toward restoring balance and ensuring that patients receive the care they deserve.

Holistic Caring & The Green Nurse and Bloom Hemp CBD are at the forefront of this mission—bridging the gap between clinical cannabis care and patient empowerment through education, advocacy, and safe, effective plant-based products. These organizations offer trusted guidance and therapeutic options that place healing back in the hands of those who need it most. By placing patients at the center of cannabis policy and practice—and partnering with leaders dedicated to that mission—we can uphold the original values of the medical cannabis movement and support equitable access to life-changing treatments.

The Green Nurse Podcast & Clinical Conversations – This month, we’re pausing our podcasts and clinical conversations to enhance our educational programs. The updated Nurse CEU-accredited content will help nurses and healthcare providers advance their professional development with Holistic Caring & The Green Nurse. Catch up on past webcast episodes here!

Cannigma Partnership – We’re excited to share that we’re now writing for The Cannigma, a top source for cannabis education and science. Expect patient-focused content blending real-world care with the latest in cannabis therapeutics. Check out our Authors Page and explore our past articles here!

Ask The Green Nurse Substack – Join “Ask The Green Nurse” with Nurse Sherri for trusted medical cannabis advice and holistic healing insights. Perfect for patients, caregivers, or the curious, she answers key questions on cannabinoids for chronic illness, pain, anxiety, and more—with science, compassion, and a touch of humor.
Ask your questions here.
Check out her past articles here.

Patients Out of Time – As longtime attendees of Patients Out of Time, we hold deep respect for the unique space this organization creates. It’s more than just a conference—it’s a gathering of minds and hearts devoted to the medical cannabis movement. Every time we attend, we’re struck by the depth of the clinical content, the integrity of the research shared, and the opportunity to connect with pioneers in cannabis and hemp science. This organization stands out for its unwavering commitment to the medical needs of all patients—especially those who are too often forgotten or left behind. In a rapidly changing industry, Patients Out of Time reminds us why we do this work: to ensure that compassionate, evidence-based care remains at the heart of cannabis medicine. Register here.

20% Savings at Bloom Hemp CBD! 

Save 20% on your entire order for the month of August. Just apply the code TOPICAL20 at checkout at www.bloomhemp.com and celebrate with a balanced body

50% Savings on all Educational Programs!

Just apply NURSE50 at checkout for the month of August at www.holisticcaring.com.
Nurses earn CEUs on all programs.

With You on The Journey,
Bloom Hemp CBD Team

References:

American Journal of Managed Care. (2022). Legalizing marijuana: How recreational marijuana legalization changes the medical use landscape. https://www.ajmc.com/view/legalizing-marijuana-how-recreational-marijuana-legalization-changes-the-medical-use-landscape
Darke, S., Banister, S., Farrell, M., Duflou, J., & Lappin, J. (2021). ‘Synthetic cannabis’: A dangerous misnomer. International Journal of Drug Policy, 98, 102296. https://pubmed.ncbi.nlm.nih.gov/34343944/
de Oliveira, M. C., Vides, M. C., Lassi, D. L. S., Torales, J., Ventriglio, A., Bombana, H. S., … & Malbergier, A. (2023). Toxicity of synthetic cannabinoids in K2/Spice: A systematic review. Brain Sciences, 13(7), 990. https://doi.org/10.3390/brainsci13070990
European Monitoring Centre for Drugs and Drug Addiction. (2021). Synthetic cannabinoids and ‘Spice’ drug profile. https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en
Giorgetti, A., Busardò, F. P., Tittarelli, R., Auwärter, V., & Giorgetti, R. (2020). Post mortem toxicology: A systematic review of death cases involving synthetic cannabinoid receptor agonists. Frontiers in Psychiatry, 11, 464. https://doi.org/10.3389/fpsyt.2020.00464
The Guardian. (2018, July 31). ‘It’s just the stuff that gets you high’: How legal weed is leaving patients behind. https://www.theguardian.com/society/2018/jul/31/oregon-cannabis-medical-marijuana-problems-sick-people
Leafwell. (2023). Recreational cannabis legalization study. https://leafwell.com/blog/recreational-cannabis-legalization-study
National Institute on Drug Abuse. (2023). Synthetic cannabinoids drug facts. https://nida.nih.gov/research-topics/synthetic-cannabinoids
ScienceDirect. (2021). The public health consequences of the commercialization of cannabinoid products. https://www.sciencedirect.com/science/article/abs/pii/S0955395921004497
ScienceDirect. (2023). Medical versus recreational cannabis use: Trends in product selection and risk. https://www.sciencedirect.com/science/article/abs/pii/S0149291823000383